Fibrolamellar Hepatocellular Carcinoma
📧 Sign up to get email alerts when something new happens for Fibrolamellar Hepatocellular Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer [Phase 1]
This Clinical Trials Update describes a Phase 1 study of an Fc-engineered anti-CTLA-4 monoclonal antibody by Agenus in patients with advance…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients [Phase 1, Phase 2]
An ongoing phase 1/2 pediatric trial examines safety and potential efficacy of a four-drug combination (cyclophosphamide, sorafenib, bevaciz…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer [Phase 1, Phase 2]
Clinical trial update for a combination of nivolumab, fluorouracil, and interferon alfa-2b in unresectable fibrolamellar hepatocellular carc…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma [Phase 1, Phase 2]
Phase 1/2 clinical trial examining the addition of DT2216 to standard chemotherapy for relapsed or refractory solid tumors and fibrolamellar…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) [Phase 1]
A Phase 1 clinical trial evaluating a DNAJB1-PRKACA fusion kinase peptide vaccine in combination with DRP-104, nivolumab, and ipilimumab for…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma [Phase 2]
A Phase 2 trial evaluating checkpoint inhibitors for pediatric hepatocellular carcinoma, including fibrolamellar hepatocellular carcinoma, i…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating DRP-104, a glutamine antagonist, in combination with durvalumab for advanced fibrolamellar hepatocellu…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma [Phase 1]
Phase 1 trial evaluating a DNAJB1-PRKACA fusion kinase peptide vaccine in combination with nivolumab and ipilimumab for fibrolamellar hepato…
-
CLINICAL_TRIALS research · 2025-11-12Clinical Trial Update: Registry to Collect Health Information Related to Fibrolamellar Cancer
A registry study collecting health information related to fibrolamellar cancer has completed.
-
CLINICAL_TRIALS research · 2025-08-05Clinical Trial Update: A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
A French multicenter observational retrospective study aimed at characterizing rare primary liver cancers, currently recruiting, including s…
-
CLINICAL_TRIALS research · 2024-12-09Clinical Trial Update: FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition [Phase 1]
A Phase 1 clinical trial at University Hospital Tuebingen evaluating FusionVAC22_01, a fusion transcript-based peptide vaccine, in combinati…